|
000
| 00899nam##2200229za#4500 |
|---|
| 001 | 9.699923 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20210625000612 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 150407|2014||||xxc|||||o f|0| 0 eng|d |
|---|
| 020 | |a978-1-100-25022-9 |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH164-184/2014E-PDF |
|---|
| 110 | 1 |aCanada. |bHealth Canada. |
|---|
| 245 | 10|aGuidance document for industry - review of drug brand names |h[electronic resource] |
|---|
| 260 | |aOttawa - Ontario : |bHealth Canada |cJuly 2014. |
|---|
| 300 | |a44p.|bfigs., references, tables |
|---|
| 500 | |a"effective date: June 13, 2015" |
|---|
| 590 | |a14-45|b2014-11-07 |
|---|
| 775 | 08|tLigne directrice à intention de l'industrie - examen des marques nominatives de médicament |w(CaOODSP)9.643864 |
|---|
| 856 | 40|ahttp://publications.gc.ca|qPDF|s314 KB|uhttps://publications.gc.ca/collections/collection_2014/sc-hc/H164-184-2014-eng.pdf |
|---|